New report highlights impact of COVID on blood cancer diagnoses
- Media releases
- Research
It’s emerging in all cancers, but particularly in the MPNs, that “genomics is everything” according to Professor Andrew Perkins, an expert in myeloproliferative neoplasms (MPN).
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
Dr Pagani has a vision for a personalised approach to treatment-free remission in CML
Dr Chun Fong believes that testing for minimal residual disease (MRD) is part of the answer.
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
Dr Piers Blombery specialises in genomic testing and heads Australia’s largest haematology laboratory.